Russo M, Malandrino P, Moleti M, Vermiglio F, D'Angelo A, La Rosa G, Sapuppo G, Calaciura F, Regalbuto C, Belfiore A, Vigneri R, Pellegriti G
Differentiated thyroid cancer in children: Heterogeneity of predictive risk factors
Pediatr Blood Cancer (ISSN: 1545-5009linking), 2018 Sep; 65(9): e27226-e27226.

Mazziotti G, Formenti AM, Panarotto MB, Arvat E, Chiti A, Cuocolo A, Dottorini ME, Durante C, Agate L, Filetti S, Felicetti F, Filice A, Pace L, Pellegrino T, Rodari M, Salvatori M, Tranfaglia C, Versari A, Viola D, Frara S, Berruti A, Giustina A, Giubbini R
Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience
Endocrine (ISSN: 1355-008x, 1355-008xlinking), 2017 Nov 06; 59(1): 90-101.

Salvatore B, Klain M, Nicolai E, D'Amico D, De Matteis G, Raddi M, Fonti R, Pellegrino T, Storto G, Cuocolo A, Pace L
Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy
Medicine (ISSN: 0025-7974), 2017 Oct; 96(42): e8344-e8344.

Marotta V, Di Somma C, Rubino M, Sciammarella C, Modica R, Camera L, Del Prete M, Marciello F, Ramundo V, Circelli L, Buonomano P, Colao A, Faggiano A
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib
Endocrine (ISSN: 1355-008x), 2015 Aug; 49(3): 854-858.

Pace L, Klain M, Salvatore B, Nicolai E, Zampella E, Assante R, Pellegrino T, Storto G, Fonti R, Salvatore M
Prognostic Role of 18F-FDG PET/CT in the Postoperative Evaluation of Differentiated Thyroid Cancer Patients
Clin Nucl Med (ISSN: 0363-9762, 1536-0229, 1536-0229electronic), 2015 Feb; 40(2): 111-115.

Pace L, Klain M, Salvatore B, Nicolai E, Zampella E, Assante R, Pellegrino T, Storto G, Fonti R, Salvatore M
Prognostic Role Of 18f-Fluorodeoxyglucose Positron Emission Tomography/Ct In The Postoperative Evaluation Of Differentiated Thyroid Cancer Patients
Clin Nucl Med (ISSN: 0363-9762, 1536-0229, 1536-0229electronic), 2015 Feb; 40(2): 111-115.

D'Antuono F, Gallicchio R, Venetucci A, Nardelli A, Giacomobono S, Pellegrino T, Tempone A, Di Leo A, Gattozzi D, Storto G
Does remnant from differentiated thyroid microcarcinoma patients really not be treated with Iodine-131 ablation?
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.

Marotta V, Ramundo V, Camera L, Del Prete M, Fonti R, Esposito R, Palmieri G, Salvatore M, Vitale M, Colao A, Faggiano A
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: Efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2013 May; 78(5): 760-767.

Barbato F, Capacchione D, Nappi A, Telesca D, Tempone A, Casolino E, Nardelli A, Castaldi E, Ortosecco G, Storto G
Does remnants from low-risk differentiated thyroid cancer patients really be not treated with Iodine-131?
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Oct; 37: N/D-N/D.

Pace L, Nicolai E, Klain M, Salvatore M
Diagnostic value of FDG PET/CT imaging
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2009; 53(5): 503-512.

Salvatore B, Paone G, Klain M, Storto G, Nicolai E, D'Amico D, Della Morte AM, Pace L, Salvatore M
Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and 131I ablation
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2008 Mar; 52(1): 2-8.

Storto G, Liuzzi R, Klain M, Albanese C, Salvatore B, Pellegrino T, Cella L, Soricelli A, Pace L, Salvatore M
Prognostic indicators in patients with differentiated thyroid cancer receiving repeated I-131 therapies
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006 Sep; 33: N/D-N/D.

Pace L, Klain M, Albanese C, Salvatore B, Storto G, Soricelli A, Salvatore M
Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006 Feb; 33(2): 179-183.

Pace L, Klain M, Soricelli A, Albanese C, Salvatore B, Storto G, Salvatore M
Short Term Outcome of Differentiated Thyroid Cancer Patients with Detectable Serum Thyroglobulin after Initial Treatment Receiving a Second 131-IODINE Therapy
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2005 Sep; 32: 179-183.

Klain M, Pellegrino T, Storto G, Biondi B, Sansone V, Pagano L, Nicolai E, Della Morte A, D'Amico D, Soricelli A, Lombardi G, Pace L, Salvatore M
Postsurgical follow up of differentiated thyroid cancer using rhTSH
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2004 Sep; 31: N/D-N/D.

Biondi B, Palmieri EA, Pagano L, Klain M, Scherillo G, Salvatore M, Fenzi G, Lombardi G, Fazio S
Cardiovascular safety of acute recombinant human thyrotropin administration to patients monitored for differentiated thyroid cancer
J Clin Endocrinol Metab (ISSN: 0021-972x), 2003 Jan; 88(1): 211-214.